K051316
Page 1 of 2

Bard Urological Division
C. R. Bard, Inc.
8195 Industrial Blvd.
Covington, GA 30014

BARD

510(k) SUMMARY OF SAFETY AND EFFECTIVENESS INFORMATION

This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990.

JUL 1 8 2005

A. SUBMITTER INFORMATION:

Submitter's Name:	C. R. Bard, Inc.
Address:	Bard Urological Division 8195 Industrial Blvd. Covington, GA 30014
Contact Person:	John C. Knorpp
Contact Person's Telephone Number:	770-784-6451
Contact Person's Fax:	770-784-6419
Date of Preparation:	May 19, 2005

B. DEVICE NAME:

Trade Name(s):	Bard® X-Force™ Nephrostomy Balloon Dilation Catheter
Common/Usual Name:	Nephrostomy Balloon Dilation Catheter
Classification Names:	78 LJE – Catheter, Nephrostomy
CFR Reference:	N/A – Unclassified

C. PREDICATE DEVICE NAME:

Trade Names: Cook® Ultraxx™ Nephrostomy Balloon Catheter

D. DEVICE DESCRIPTION:

The Bard® X-Force™ Nephrostomy Balloon Dilation Catheter is composed of a dual lumen shaft with inflation and guidewire lumens and a dilation balloon on the distal end. The catheter has a radiopaque band which corresponds with the distal end of the balloon's working length to facilitate radiographic visualization and placement. A high pressure stopcock is used on the inflation lumen to maintain pressure after removal of the pressurization apparatus.

E. INTENDED USE:

The Bard® X-Force™ Nephrostomy Balloon Dilation Catheter is recommended for use in the dilation of the nephrostomy tract and for placement of the working sheath.

F. TECHNOLOGICAL CHARACTERISTICS SUMMARY:

The subject Bard® X-Force™ Nephrostomy Balloon Dilation Catheter has the same intended use, general design and fundamental scientific technology as the predicate device.

G. PERFORMANCE DATA SUMMARY:

The appropriate testing to determine substantial equivalence was completed. This includes testing in accordance with *Draft Guidance for the Content of Premarket Notifications for Urological Balloon Dilation Catheters* (January 24, 1992).

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JUL 1 8 2005

Mr. John C. Knorpp
Manager, Regulatory Projects
Bard Urological Division
C.R. Bard, Inc.
8195 Industrial Blvd.
COVINGTON GA 30014-2655

Re: K051316
Trade/Device Name: Bard® X-Force™ Nephrostomy Balloon Dilation Catheter
Regulation Number: None
Regulatory Class: Unclassified
Product Code: LJE
Dated: May 19, 2005
Received: May 20, 2005

Dear Mr. Knorpp:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Nancy C. Brogdon

Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

1.3 Indications for Use Statement

510(k) Number (if known): K051316

Device Name: Bard® X-Force™ Nephrostomy Balloon Dilation Catheter

Indications for Use:

The Bard® X-Force™ Nephrostomy Balloon Dilation Catheter is recommended for use in the dilation of the nephrostomy tract and for placement of the working sheath.

Prescription Use X AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE –
CONTINUE ON ANOTHER PAGE IF NEEDED)

CONCURRENCE OF CDRH, OFFICE OF DEVICE EVALUATION (ODE)

Nancy C. Brogdon
(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices
510(k) Number K051316

(Recommended Format 11/13/2003)